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Absorption, distribution, metabolism and
excretion of selenium following oral
administration of elemental selenium
nanoparticles or selenite in rats†
Katrin Loeschner,a Niels Hadrup,a Marianne Hansen,a Sonia A. Pereira,a
Bente Gammelgaard,b Laura Hyrup Møller,b Alicja Mortensen,a Henrik Rye Lama
and Erik H. Larsen*a
A suspension of nanoparticles of BSA-stabilized red amorphous elemental selenium (Se) or an aqueous
solution of sodium selenite was repeatedly administered by oral gavage for 28 days at 0.05 mg kg1 bw
per day (low dose) or at 0.5 mg kg1 bw per day (high dose) as Se to female rats. Prior to administration,
the size distribution of the Se nanoparticles was characterized by dynamic light scattering and transmission
electron microscopy, which showed that the particles’ mean diameter was 19 nm and ranged in size from
10 to 80 nm. Following administration of the high dose of Se nanoparticles or selenite the concentration of
Se was determined by ICP-MS in the liver, kidney, urine, feces, stomach, lungs, and plasma at the mg g1
level and in brain and muscle tissue at the sub-mg g1 level. In order to test if any elemental Se was present
in the liver, kidney or feces, an in situ derivatization selective to elemental Se was performed by treatment
with sulfite, which resulted in formation of the selenosulfate anion. This Se species was selectively and
quantitatively determined by anion exchange HPLC and ICP-MS detection. The results showed that
elemental Se was present in the livers, kidneys and feces of animals exposed to low and high doses of
elemental Se nanoparticles or to selenite, and was also detected in the same samples from control animals.
The fraction of Se present as elemental Se in livers and kidneys from the high dose animals was
significantly larger than the similar fraction in samples from the low dose animals or from the controls.
This suggested that the natural metabolic pathways of Se were exhausted when given the high dose
of elemental Se or selenite resulting in a non-metabolized pool of elemental Se. Both dosage forms of
Se were bioavailable as demonstrated by the blood biomarker selenoprotein P, which was equally
up-regulated in the high-dose animals for both dosage forms of Se. Finally, the excretion of Se in urine and
its occurrence as Se-methylseleno-N-acetyl-galactosamine and the trimethylselenonium-ion demonstrated
that both dosage forms were metabolized and excreted. The results of the study showed that both forms
of Se were equally absorbed, distributed, metabolized and excreted, but the detailed mechanism of the fate
of the administered elemental Se or selenite in the gastro-intestinal tract of rats remains unclear.
Introduction
Selenium (Se) and its metabolites occur in organisms from a
range of phyla including microorganisms, fungi, plants, animals
and humans and is incorporated into Se-proteins such as the
antioxidant enzymes glutathione peroxidases or selenoprotein-P
(SelP), a transport protein for Se. Current reports on the
metabolism of Se have proposed that the metabolic cycle and
excretion from humans include both inorganic and organic
molecular species of Se present at various oxidation states
including 2, +2, +4 and +6.1 The formation of elemental Se
(oxidation state 0, Se0) has less often been studied as part of
metabolic processes.2 Nevertheless, Se0 has been reported to
occur in soils where microbes drive the redox cycle between on
one hand the oxidized species selenate (Se(VI)) and selenite
(Se(IV)) and on the other hand the reduced Se0.3 Furthermore,
Se(IV) can be reduced to nanometer-sized particles of Se0 by
fungi, which expelled the nanostructures through their cell
membrane as a protective mechanism.4 Following enrichment
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of a culture of Lactobacillus bulgaricus with Se(IV), amorphous
Se0 nanoparticles (Se0NPs) were formed outside and inside their
cytosol, and this Se0-enriched culture was suggested as a safe
dietary source of Se.5 Transmission electron microscopy (TEM)
with element-selective energy-dispersive X-ray fluorescence
(EDX) proved to be a convenient tool in these studies for imaging
of the Se0NPs and to provide evidence of their identity.
The absorption rate of Se0 obtained from bacteria was tested
and showed a modest availability in chickens at 2% of that of
Se(IV).6 Synthetically made Se0NPs have been selectively engineered
as novel Se supplements by derivatizing their surface with bio-
inspired materials such as a polysaccharide to improve the
stability of the NPs,7 or by using a catechin-derivative8 to allow
pH-dependent stability against aggregation in liquid suspen-
sion prior to biological experimentation. In the search for a
bioavailable and bioactive, yet non-toxic form of Se, red Se0NPs,
which were synthesized in the presence of and stabilized by
bovine serum albumin (BSA), were orally administered to rats.
The results showed a high degree of bio-activity comparable
with that of Se(IV) as Se-dependent enzymes were up-regulated,
yet the acute and short-term toxicities were lower than that of
Se(IV).9,10 In order to further investigate its potential as a chemo-
preventive agent, the toxicity of Se0NPs was compared with that of
selenomethionine (SeMet)11 or methylselenocysteine (MeSeCys) in
a short-term study with mice.12 The results showed less toxicity of
the nanoform, and Se0NPs were as eﬃcient as the two molecular
Se forms in inducing the formation of Se-dependent enzymes.
In a sub-chronic toxicity study with rats, the nano-Se source
was inferior in toxicity to that of Se(IV) or Se-rich protein used
as sources of Se.13 Combined these results demonstrated a
beneficial, lower acute and sub-chronic toxicity of Se0. When
used as a feed additive Se0NPs improved the intrinsic immune-
defense system of sheep, rumen fermentation as well as utiliza-
tion of the animals’ feed.14,15
Regarding the Se retention in blood and tissues of experimental
animals, no significant diﬀerence in the selenium concentration in
blood, liver and kidneys was observed after 7 days of repeated
administration of Se0NPs or MeSeCys to mice at nutritional levels
(0.035 and 0.070mg kg1 bw per day). However, when administering
a supra-nutritional dose (1mg kg1 bw per day) the Se concentration
was higher in the MeSeCys exposed animals.12 Similar observations
have been made when comparing Se0NPs with SeMet.11
Methods for detection and quantitative determination of Se0
in liquid suspension included reaction of the Se0 analyte with a
sulfide followed by spectrophotometric absorbance measurements
of the reaction product.16 A method for determination of Se0 in liver
homogenates and in red blood cell lysates was based on the
reduction of Se0 by sodium sulfite to form the selenosulfate-ion
(SeSO3
2). The concentration of Se0NPs was calculated from the
diﬀerence in Se concentration in the sample (no sulfite treatment)
and that in the supernatant of the sulfite-treated sample.12 The
indirect nature of this analytical approach would benefit from a
more direct method of analysis for the SeSO3
2 reaction product.
The aim of the present study was to investigate the absorp-
tion, distribution, metabolism and excretion (ADME) of Se0NPs
stabilized with BSA in rats that were repeatedly exposed via oral
gavage for 28 days. Two doses of Se, one close to physiological
dose at 0.05 mg Se per kg bw per day or one supra-nutritional
dose at 0.5 mg Se per kg bw per day, were administered daily.
For comparison Se(IV) was used as positive control. In order to
most accurately describe the ADME of Se, its concentrations
were determined in selected tissues, feces and urine using
state-of-the-art mass spectrometric methods of analysis for Se
and Se species analysis. Dynamic light scattering (DLS) or TEM
were used for characterization of the particle size in the Se0NP
suspension prior to dosage.
Experimental
Selenium nanoparticles and chemicals
A suspension of red amorphous Se0NPs was synthesized by
reduction of sodium selenite with glutathione in the presence of
BSA as described in detail elsewhere.9 A solution of 0.2 M sodium
sulfite (BRR, Prolabo, Leuven, Belgium) was prepared in ultra-pure
water, which was obtained from a Millipore Element apparatus
(Millipore, Milford, MA, USA). The pH of the freshly prepared
solution was 9.5. The solvents used for the high performance liquid
chromatography (HPLC) analyses were freshly He-degassed ultra-
pure water and methanol (Rathburn Chemicals Ltd., Walkerburn,
Scotland). Solutions of selenocystine (SeCys2) (Sigma-Aldrich,
Copenhagen, Denmark) and of selenodiglutathione (GSSeSG)
(PharmaSe, Lubbock, TX, USA) were prepared in He-degassed
ultra-pure water. Aqueous solutions of selenite (Se(IV)), selenate
(Se(VI)) and selenomethionine (SeMet) were prepared as described
previously.17
Characterization of the Se0 nanoparticle suspension
The concentration of Se in the suspension of Se0NPs was
determined following digestion by nitric acid (see the following
section on Se analysis) by inductively coupled plasma mass
spectrometry (ICP-MS) (7500ce, Agilent Technologies, Japan) run in
the collision-reaction cell (CRC) mode with He as interference-
reducing cell gas. The content of non-particulate Se in the suspen-
sionwas determined following filtration through a 12 kDamolecular
weight cut-oﬀ cartridge (VectaSpin Micro Centrifuge Filter,
Whatman, England) at 13 400 rpm (12 100  g) for 10 minutes
in a microcentrifuge (Eppendorf MiniSpin, Eppendorf AG,
Hamburg, Germany). After digestion the acidic samples were
diluted with a mixture of ultra-pure water and 3% methanol18
to approximately 2% nitric acid concentration. The concentration
of Se was quantified using external calibration with yttrium (Y) as
the internal standard (SCP Science, Quebec, Canada). The limit
of detection (3s) was 17 and 2 mg Se per mL for the suspensions
and filtrates, respectively.
The size distribution of each produced batch was determined
by DLS and laser Doppler velocimetry was used for characteriza-
tion of zeta-potential of the nanoparticles in suspension using a
Zetasizer Nano-ZS (Malvern Instruments, UK). After equilibration
of the sample to a temperature of 25 1C, five measurements
were performed with 12 runs of 10 seconds each. The laser
power (attenuator index) and the measurement position within
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the cuvette were determined automatically by the instrument.
For the calculation of the nanoparticle size distribution
the viscosity of water was used. The optical parameters for
selenium’s index of refraction n = 3.37 and index of absorption
k = 0.52 at 633 nm were applied.19
The size and shape of the Se0NPs were imaged by TEM
using a TEM Philips CM100 instrument (FEI, Eindhoven, The
Netherlands) at 80 kV accelerating voltage. Prior to recording,
the Se0NP suspension was diluted 10 times with deionized
water. A drop of the suspension was applied to a formvar-coated
copper grid.
Instrumentation
For the chromatographic separation of Se species, the HPLC flow
was delivered using a quaternary, metal-free HPLC pump and an
autosampler. Details of the anion exchange chromatographic
system used for SeSO3
2 separations, the heparin-aﬃnity HPLC
system used for SelP analysis and the reversed-phase or cation
exchange HPLC systems used for urine metabolites20,21 are given
in ESI,† Table S1. Integration of chromatographic peaks was
carried out using Total Chrom software version 6.3. For the low-
level Se determinations in tissues, and for Se detection following
HPLC separations, the ELAN 6100 ICP-DRC-MS instrument
(Perkin Elmer SCIEX, Concord, Ont., Canada) was used in the
dynamic reaction cell (DRC) mode for reduction of polyatomic
interferences on 77Se, 78Se and 80Se. For Se speciation in urine
82Se was monitored using an ELAN 6000 ICP-MS instrument.
Instrumental details for ICP-DRC-MS and for HPLC instrumen-
tation were as described previously.22,23
Animal study
Four week old female Wistar Hannover Galas rats with a specific
pathogen-free health status were purchased from M&B Taconic
(Lille Skensved, Denmark). Upon arrival the rats were allowed to
acclimatize for a week before the start of the experiment. The
body weight of the animals at the beginning of the study was
(mean  one s.d.) 132  15 g (N = 44). The rats were housed
conventionally with two animals per cage (Macrolon, Techniplats
Gazzada S. ar. L., Buguggiate, Italy) with a 12 : 12 h reversed
light–dark cycle from 7 p.m. to 7 a.m. The room temperature was
22 1 1C and the relative humidity was 55% 5%. The rats were
given ad libitum a standard diet (Altromin rat No.1324, Brogården,
Gentofte, Denmark) and citric acid acidified (pH 3) tap water to
avoid microbiological contamination of drinking water. The
composition of the standard feed provided the animals with all
necessary nutrients including an intake of vitamin E of
5.7 mg kg1 bw per day. The animal study was performed
under conditions approved by the Danish Animal Experiments
Inspectorate and the in-house Animal Welfare Committee.
The rats were randomized into six groups, two of which
during 28 consecutive days once daily orally by gavage received
100 mL kg1 bw of either deionized water (N = 8) or
100 mL kg1 bw of an aqueous solution of 4 g L1 of bovine
serum albumin (N = 8) as vehicle controls (St. Louis, MO, USA).
The BSA-stabilized suspensions of Se0NPs were dosed at 0.05 or
0.5 mg Se per kg bw per day (N = 6 per group), or aqueous
solutions of the Se(IV) sodium salt were dosed at the same two
doses (N = 8 per group). On day 15 of the study the rats were
placed individually for 24 hours in metabolism cages for
collection of urine and feces on dry ice. During this time the
animals had access to water, but not to feed. On day 28 the rats
were fasted overnight before euthanization on day 29 where
they were anaesthetized in CO2/O2 and decapitated. Blood from
the neck wound was collected on heparin and plasma was
prepared by centrifugation (1000  g at 0 to 4 1C for 10 min)
and organs were removed. From six animals from each of the
groups exposed to 0.5 mg kg1 bw per day of Se0NPs or Se(IV),
the stomach (corpus ventriculi), muscle (right biceps femoris) and
brain, which were transferred to ice-cold 0.32 M sucrose and
homogenized by focused ultrasound, were reserved for chemical
analysis. From the same animals, the liver (lowest part of the
left median lobe), left kidney and feces were sampled for total
Se and Se0 analysis, whereas blood plasma was subjected to
total Se and SelP analysis.
Sample preparation and analysis of Se, SelP and elemental Se
Sub-samples of animal organs were mixed with nine times
excess of ultra-pure water in a 50 mL polyethylene tube and
homogenized using an Ultra Turrax homogenizer (DI 25 Basic,
Ika-Werke, Staufen, Germany). The homogenates were frozen
and stored at 18 1C until time of analysis. The complete feces
were collected and dried at 80 1C for 4 days. The dry samples
were homogenized using a mortar and pestle and stored in a
desiccator until time of analysis. The content of Se in the biological
samples, in the Se0NP-suspension and in the filtrates were deter-
mined by ICP-DRC-MS following microwave-assisted wet-ashing
by nitric acid of 300 mg of tissue, 100 mg of feces or 1 mL of
urine using a methodology described previously.17
The thawed blood plasma samples were passed through a
0.45 mm filter (Whatman Mini-UniPrep, Clifton, NJ, USA) and
subjected to separation of the SelP by heparin aﬃnity HPLC
(Table S1, ESI†). Quantification was carried out using post-column
isotope dilution using an enriched (99.2%) 77Se standard.24 The
enriched isotope (10 ng Se per mL using mobile phase A as solvent)
was pumped using a peristaltic pump and its accurate flow was
monitored daily by weighing. The enriched stable isotope and the
eluent from the HPLC column were mixed via a T-piece before
entry into the nebulizer of the ICP-DRC-MS, which was used to
detect the spike isotope (77Se) and the reference isotope (80Se) at
50ms dwell time per mass for the duration of the chromatographic
separation. Corrections were made daily for mass bias.
Then thawed urine samples were diluted (1 + 1) by the mobile
phase and filtered prior to analysis. The separated Se species were
quantified by external calibration by use of a single authentic
standard of the respective Se species as the calibrant.
For control of accuracy of Se analyses in organs and feces
the certified reference material (CRM) Bovine Liver (BCR CRM
185R No. 69, Geel, Belgium) with a certified value for Se of
1680  140 ng g1 was included in each batch of analyses.
The values obtained were corrected for the dry matter content
of 93.2%. For determination of Se in urine samples the
RM Seronormt Trace Elements Urine (Nycomed Pharma
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Diagnostics, Oslo, Norway) with a reference value for Se of
58.6 ng Se per mL was used.
For the in situ synthesis of the ion in tissues and feces,
500 mL of the organ homogenate or 50 mg of the dry feces
containing Se0 were mixed with 250 mL of the 0.2 M sulfite
solution and water to a final volume of 1500 mL. The mixture
was placed in a flat bottom glass vial in a water bath at 50 1C
for 20 minutes using magnetic stirring. After cooling, the
mixture was purified by passage through a disposable C18 filter
cartridge mounted in series with a membrane filter with a
0.45 mm pore size. Prior to HPLC analysis, sub-samples of
one for every ten of the sulfite-treated control samples were
spiked with 0, 100 or 200 ng Se per mL as Se(VI), which was
co-chromatographed and used to construct a standard addi-
tions calibration curve for Se on the basis of chromatographic
peak area. Anion exchange HPLC (Table S1, ESI†) was used to
separate the synthesized SeSO3
2, which corresponded to the
original content of Se0, from the spiked Se(VI) calibrant and
other naturally occurring Se-species in the sample.
The contents of Se or Se species in the biological materials
were compared using Student’s two sample t-test ( p o 0.05)
after the F-test of the equality of variances (Excel, Microsoft
Corporation, WA, USA).
Results and discussion
Se0 nanoparticle characterization
The size distribution of the Se0NPs in BSA solution determined
by DLS is shown in Fig. 1. The major fraction of the nano-
particles had a diameter in the range of 10 to 80 nm with a
maximum of the size distribution (mean  one s.d.) at 19 
1 nm. A small fraction of the Se0NPs was present as micrometer
sized aggregates, which could not be dispersed by ultrasound.
The size distribution was determined immediately before
and after the animal study to ensure that nanoparticles with
the same size characteristics were administered to the rats
throughout the animal study. Transmission electron micro-
scopy (Fig. 1) confirmed the determined diameter and showed
that the particles had a spherical shape. The total selenium
concentration in the suspensions was (mean  one s.d.) 380 
3 mg mL1. The amount of unbound selenium was undetectable
(o2 mg mL1) showing that all administered Se was in the form
of nanoparticles.
Absorption and distribution of Se
The animal study included two Se dose levels for each
chemical form, i.e. Se0NPs and Se(IV). The low dose at
0.05 mg Se per kg bw per day was chosen as toxicological
eﬀects were not expected, and the high dose at 0.5 mg Se per kg
bw per day was chosen as a supra-nutritional dose where
toxicological eﬀects were likely to occur.12,13 The intrinsic Se
concentration in the rats’ feed was (mean  one s.d.) 250 
54 ng g1 (N = 3), which influenced the Se content in the control
animals. Considering an average consumption of feed for a rat
of around 15 g per day, the control animals received about
0.03 mg Se per kg bw per day via the feed. The distribution of Se
in a range of organs, blood plasma, urine and feces from rats,
that were administered the highest dose, and in corresponding
controls, was analyzed by ICP-DRC-MS (Fig. 2). The largest
concentrations were detected in the metabolically active organs
liver and kidneys. The Se contents in most biological samples
were not diﬀerent for the two dosage forms. In lungs however,
the Se content was higher following dosage with Se(IV), but the
reason for this slightly higher content remains unknown. The
results in Fig. 2 demonstrated that the bioavailability in rats of
Se0NPs was similar to that observed for Se(IV) as indicated by
the plasma concentrations. For the animals, which received
0.5 mg Se per kg bw per day the recovery of Se in their feces
amounted to (mean  one s.d.) 12  5% and 13  5% of the
daily doses of Se0 or Se(IV), respectively. The similar urinary
excretions were 45  4% and 53  10% of the daily doses.
Fig. 1 Size characterization of Se0NPs by DLS and TEM.
Fig. 2 Se concentrations (mean  s.d.) in rat organs, blood plasma, feces
and urine following administration of 0.5 mg Se per kg bw per day.
All values were significantly diﬀerent from corresponding controls
(po 0.001). For lungs the Se values following dosage of Se(IV) were higher
(p = 0.002) than those following dosage of Se0NP.
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Analysis and occurrence of Se0 in liver, kidneys and feces
Given the finding that both administered Se forms were absorbed
by rats, the question was in which chemical or physical form it was
present. Bearing in mind that intact selenium nanoparticles were
reported in livers following oral administration of BSA-stabilized
Se0NPs tomice,12 it was decided to test if Se0 occurred in the organs
from the present work. The most straightforward way would be to
apply an imaging method and screen for the presence of Se0NPs.
Given that the mean diameter of the dosed Se0NPs was approxi-
mately 20 nm and that the liver tissue concentration of Se was
approximately 5 mg g1, the number density however, was too low
for any successful imaging of Se0NPs by TEM. Therefore, anion
exchange HPLC-ICP-MS was used following in situ derivatisation of
Se0 with sulfite to SeSO3
2.12,25,26
The usefulness of the method based on in situ derivatisation
of Se0 in biological materials depended on its selectivity,
accuracy and on possible associated matrix eﬀects. In order
to test the selectivity of the derivatisation method to Se0, Se
species that are known to occur in biological materials, and
therefore could interfere during the sulfite reaction, were
taken through the derivatisation procedure and the reaction
product analysed by anion-exchange HPLC-ICP-MS. The results
in Fig. 3 demonstrated that the method was selective to Se0,
with the exception of GSSeSG for which a small HPLC peak
co-eluted with the reaction product between Se0NPs and sulfite,
i.e. SeSO3
2 (lower trace). This could be caused by instability of
the selenotrisulfide, which was observed to degrade at neutral
or alkaline pH followed by formation of elemental Se.27 The
method was applied to the analysis of Se0 in the biological
samples and an example chromatogram is shown in ESI,†
Fig. S0. The influence of the reaction time between sulfite
and Se0 on the yield of SeSO3
2 showed that reaction times
longer than 20 minutes gave no further yield of this Se species,
which was stable only for a few hours in the pre-treated biological
tissue (ESI,† Fig. S1). The samples therefore had to be analyzed
within a short time interval from the sample pre-treatment.
Absolute recoveries of Se following spiking with Se0NPs to liver,
kidneys or feces were 64–72%, and possible matrix effects on the
calibration curves based on spiking with Se(VI) were undetectable
as shown in ESI,† Fig. S2.
The quantitative results for the content of Se0 in liver,
kidneys and feces are given in Fig. 4 as a fraction of total Se
in each biological sample. The results demonstrated that Se0
was indeed detected in the biological materials from animals
following administration of Se0NPs or Se(IV) at both dose levels.
The intake of Se from the feed was 0.03 mg kg1 bw per day,
which yielded detectable Se0 at around 5–10% of the total Se
concentration in the control samples. For the rats, which were
dosed 0.05 mg kg1 bw per day, the liver and kidney samples
also showed a content of Se0, which did not differ from the
corresponding controls and did not depend on the dosage form.
This suggested that the metabolic potential of Se in these organs
was sufficient to convert the administered Se via natural pathways.
In contrast, in the samples from rats, which were administered
the ten times higher dose, i.e. 0.5 mg kg1 bw per day, the
Fig. 3 Anion exchange HPLC-ICP-MS chromatograms of 150 ng Se per
mL of authentic Se standards, and 1000 ng Se per mL of Se0NPs treated
with sulfite leading to formation of SeSO3
2. See the Methods section for
further details.
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relative amount of Se0 in liver and kidneys increased significantly
from 2 to 7% in the control and low dose animals to between 17 and
40% of the total Se concentration in these organs. This increase
could be explained by exhaustion of the natural reductive pathway
by glutathione (GSH) leading to formation of Se0 via formation of
unstable GSSeSG or selenopersulfide intermediates.2,28 Under
such circumstances the risk of Se toxicity may be prevalent due
to the associated possible oxidative damage.29 The relative
excretion of Se0 in feces was generally higher from animals that
received Se0NPs than those receiving Se(IV), which indicated a
lower absorption of Se0NPs. The finding of Se0 in the feces also
from the Se(IV) dosed group of animals can be explained by
bacterial reduction of Se(IV) to Se0.30
Selenoprotein P as a blood biomarker for exposure to Se0NPs
The bioavailability and incorporation of Se into Se-proteins was
monitored by SelP in plasma. Because synthesis of seleno-
proteins occurs as part of the suggested metabolic pathway of
Se in animals and humans, the up-regulation is considered to
express that both forms of administered Se were available to
the pathway.1 The content of SelP in plasma was analysed by
aﬃnity HPLC-ID-ICP-MS as shown by the example chromato-
gram in ESI,† Fig. S3. The final results were calculated on the
basis of the ratio of 77Se to 80Se. The results in Fig. 5 show
for both dose levels of Se(IV), that SelP was expressed to a
higher concentration than that in the corresponding controls.
Following the administration of two doses of Se0NPs to the rats
however, this increase was observed only for the high dose of
0.5 mg kg1 bw per day. Because the levels of SelP in plasma
were not significantly diﬀerent in the high dose Se0NPs group
as compared with Se(IV), it is concluded that both forms of
Se are equally bioavailable and cause an equal up-regulation
of SelP in rats. The same conclusion was drawn for the
liver, plasma and kidney glutathione peroxidases (GPx) in mice
supplemented with Se0NPs or Se(IV), but for up-regulation of
thioredoxin reductases (TrxR) in liver and kidneys, Se(IV) was
more eﬃcient than Se0NPs.9,12 The present findings in rats and the
previously published results for mice indicate that the investigated
Se-proteins were up-regulated dependent on the supplemented
dose of Se, but largely independent of its chemical form.
Excretion of Se in urine
The excretion of Se (Fig. 2) and Se species metabolites was
studied in urine by HPLC-ICP-MS. Despite the fact that the level
of the glutathione may have been influenced by the animals’
fasting at the day of collection of urine, and knowing
that this reductant influences the metabolism of Se in rats,
still the state of fasting is relevant both to animals and to
humans e.g. while sleeping, or after the postprandial period.
Representative chromatograms (ESI,† Fig. S4) show that the
selenosugar, Se-methylseleno-N-acetyl-galactosamine (SeGalNAc)
and trimethylselenonium-ion (TMSe+) were detected and the
semi-quantitative results are presented in Fig. 6. It appears that
for animals treated with Se0NPs, the concentrations of SeGalNAc
are higher in the low dose animals compared to high dose
animals, while the opposite pattern was observed in the animals
dosed with Se(IV). However, the variation between animals is very
large. The results in Fig. 6 are given as urine concentrations, and
calculation of total excreted Se did not change this pattern. No
TMSe+ was detected in controls and low dose animals, while
large amounts were observed in both high dose groups. When
calculating the percentage of Se excreted as SeGalNAc and
TMSe+, respectively (ESI,† Table S2), it appeared that in low dose
animals that received both Se forms and in controls, about 70%
of the Se content was excreted as SeGalNAc, while the average
excretion of this Se species in high dose animals was around 20%.
Fig. 4 Elemental Se (Se0) as a percent of total Se (mean  s.d.) in rat liver,
kidneys and feces. Columns correspond to administration of Se0NPs or
Se(IV) (mg Se per kg bw per day) or controls.
Fig. 5 Concentration of selenoprotein P (SelP) in rat plasma (mean  s.d.)
following administration of Se as Se0NPs or Se(IV) at low or high doses
(mg kg1 bw per day). The stars indicate the level of significant diﬀerence
between dosage and control. The results corresponding to high doses of
Se0NP and Se(IV) were not significantly diﬀerent.
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At the same time the TMSe+ excretion increased to about 50%
in both high dose groups. Thus, the average excretion patterns
of SeGalNAc and TMSe+ were identical after Se0NP or Se(IV)
administration. SeGalNAc is the major metabolite in urine,31,32
while the presence of TMSe+ is dose dependent in rats.33 The
finding that the relative TMSe+ excretion increases with increasing
doses of selenite in rats is thus in accordance with previous results
for young rats,33 although the studies on groups of animals are
limited and no speciation data on Se excretion after Se0NP
administration have been published before.
Possible conversions of Se in the gastro-intestinal tract of rats
prior to absorption
Following oral administration by gavage of Se as Se0NPs or Se(IV)
the dosed forms may undergo changes under the influence of
the diﬀerent physico-chemical and microbial conditions existing
in the compartments of the gastrointestinal tract of rats. The
similar concentration of Se found in the blood and the organs
following oral administration of Se as Se0NPs or Se(IV) (Fig. 2)
and the similar fraction of Se0 herein (Fig. 4) suggest that the two
chemical forms were metabolized following similar pathways.
Such pathways may include that Se(IV) was reduced to Se0, or
that Se0NPs became dissolved and oxidized to inorganic oxo-
anions of Se, as both reactions were possible in a microbial
environment.3,34 Such conversions were demonstrated using the
intestinal contents from rats as medium and it was shown that
Se(IV) was reduced to red elemental Se0 by the gut microflora.30 In
a study with broiler chickens, the animals were dosed with 75Se(IV)
or as BSA-stabilized 75Se0NPs at approximately the same size as
used in the present study.35 The results showed that the nano-
particles were more eﬀectively absorbed by the chickens in
comparison with Se administered as Se(IV). The authors suggested
that the Se0NPs were absorbed directly from the intestine, but did
not present any direct evidence to support this.
Alternatively, the dosed BSA-stabilized Se0NPs may become
dissolved in oxidized segments of the gastrointestinal tract and
possibly form Se(IV) via microbial or chemical activity.35 In
this case, Se(IV) would be absorbed passively in a similar
fashion for both dosage forms, and such a route would support
our findings. Furthermore, the slightly higher content of Se and
higher proportion of Se0 in feces from animals given the Se0NPs
in this study (Fig. 2) lends credit to this fate of Se0NPs in rats.
Conclusions
In conclusion, our studies have shown that Se from Se0NPs was
absorbed and distributed to organs and excreted to the same
extent as that observed for Se administered as Se(IV) used as
positive control. The bioavailability of nanoparticulate elemental Se
was derived from the finding of SelP in plasma. The entry of Se0NPs
into the metabolic pathway and its subsequent excretion was proven
by the detection of the urinary metabolites Se-methylseleno-N-acetyl-
galactosamine and TMSe+ and furthermore indicated by the similar
excretion patterns in rats’ urine after dosage of Se0NPs or Se(IV).
The high relative amount (tens of percent) of Se0 found in liver
and kidneys of animals receiving the high dose of Se0NPs or
Se(IV) suggested a dissimilarity in metabolism in the animals
that received low dose or controls. The possible toxic reaction
associated with the high dose triggered further study of selenium
toxicity following exposure to Se0NPs, which is now underway
in our group. The fate and mechanisms behind the possible
conversions of Se in the gastrointestinal tract of rats to shed
light on which pathways are active prior to absorption need
further elucidation. The aim of such research would be to
answer the question whether Se dosed as Se(IV) is reduced to
Se0 and absorbed as such, or whether Se0 becomes oxidized
to oxo-anions of Se before absorption.
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